Artemis Health
+20%
est. 2Y upside i
Rank
#1605
Sector
Healthcare Technology
Est. Liquidity
~4Y
Data Quality
Data: LowArtemis Health's equity offers a modest expected upside of ~20% over 2 years, weighed down by a 50% bear probability from incumbent threats and stale valuation.
Last updated: July 3, 2026
Revenue reaches $47M by 2028; exit multiple expands to 10x on IPO window and category leadership, yielding $470M exit. Common equity appreciates 232% before dilution.
Revenue grows to $47M, exit multiple converges to 6x within comp range, yielding $282M exit. Common equity gains 70.6% before dilution.
Growth decelerates due to incumbent pressure; revenue hits $47M but exit multiple compresses to 3x, yielding $141M exit. Common equity loses 50.8% before dilution; after dilution -70.8%.
Preference Stack Risk
severeFunding Intensity
41300%Total funding of $83.8M represents 41.9% of current valuation, creating significant preference overhang.
Dilution Risk
highNo funding since 2019 and negative revenue momentum suggest a dilutive round is likely within 2 years; estimated 20% dilution.
Secondary Liquidity
noneNo secondary market activity; part of private Nomi Health with no known tender offers.
Questions to Ask at the Interview
Strategic questions based on Artemis Health's data — designed to show you've done your homework.
- 1
“How does Artemis plan to differentiate against Optum and Evernorth's scale and data capabilities?”
- 2
“What is the current subscription renewal rate and net dollar retention?”
- 3
“What is the expected timeline to profitability or next funding round, and how does that impact employee equity?”
Community
Valuation Sentiment
Our model estimates +20% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.